9.77
-0.92 (-8.65%)
| Penutupan Terdahulu | 10.69 |
| Buka | 10.72 |
| Jumlah Dagangan | 249,037 |
| Purata Dagangan (3B) | 841,748 |
| Modal Pasaran | 78,055,160 |
| Harga / Buku (P/B) | 10.04 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 Aug 2025 |
| EPS Cair (TTM) | -12.30 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 131.68% |
| Nisbah Semasa (MRQ) | 0.550 |
| Aliran Tunai Operasi (OCF TTM) | -17.91 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -6.55 M |
| Pulangan Atas Aset (ROA TTM) | -62.86% |
| Pulangan Atas Ekuiti (ROE TTM) | -244.55% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Cel-Sci Corporation | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 3.5 |
| Purata | 1.63 |
|
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 0.98% |
| % Dimiliki oleh Institusi | 3.80% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Mai Capital Management | 30 Jun 2025 | 64,933 |
| Chilton Capital Management Llc | 30 Jun 2025 | 3,531 |
| Archer Investment Corp | 30 Jun 2025 | 1,000 |
| Hyperion Partners, Llc | 30 Sep 2024 | 553 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |